Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sodium valproate: monotherapy and polytherapy.

A Covanis, A K Gupta, P M Jeavons

    Epilepsia
    |December 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Improving the diagnostic yield in Panayiotopoulos syndrome.

    European journal of neurology·2008
    Same author

    [Congenital hemiplegia. A disease with manifold problems].

    Der Nervenarzt·2007
    Same author

    Role of valproate across the ages. Treatment of epilepsy in children.

    Acta neurologica Scandinavica. Supplementum·2006
    Same author

    Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

    Neurology·2005
    Same author

    Subacute sclerosing panencephalitis after intrauterine infection.

    Acta paediatrica (Oslo, Norway : 1992)·2004
    Same author

    Association of the connexin36 gene with juvenile myoclonic epilepsy.

    Journal of medical genetics·2004

    Sodium valproate (VPA) is an effective monotherapy for epilepsy, achieving seizure freedom in over 80% of patients with primary generalized seizures. VPA demonstrates a favorable safety profile with uncommon side effects, even during pregnancy.

    Area of Science:

    • Neurology
    • Clinical Pharmacology
    • Epileptology

    Background:

    • Sodium valproate (VPA) has been utilized for epilepsy management since 1973.
    • Understanding VPA's efficacy and safety in diverse epilepsy types is crucial for treatment optimization.

    Purpose of the Study:

    • To evaluate the long-term efficacy and safety of VPA monotherapy in a large patient cohort.
    • To determine optimal VPA dosing and serum levels for seizure control.
    • To assess VPA's teratogenicity during pregnancy.

    Main Methods:

    • Retrospective analysis of 605 epilepsy patients treated with VPA since 1973.
    • Assessment of seizure control, side effects, and serum VPA levels.
    • Review of pregnancy outcomes in patients on VPA monotherapy.

    Related Experiment Videos

    Main Results:

    • 200 out of 240 patients on VPA monotherapy achieved seizure freedom (83.3%).
    • High efficacy (>80%) observed in absence, myoclonic, and primary tonic-clonic seizures.
    • VPA demonstrated good tolerability with uncommon side effects; weight increase was most frequent. No severe hepatic disorders or teratogenicity reported in monotherapy pregnancies.

    Conclusions:

    • VPA is highly effective as monotherapy for primary generalized epilepsy.
    • Once-daily VPA dosing was found to be more effective than twice-daily.
    • VPA offers a favorable safety profile, particularly at doses not exceeding 40 mg/kg or 2.5 g daily.